APA (7th ed.) Citation

Varga, A., Piha-Paul, S., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., . . . Matei, D. (2019). Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecologic Oncology, 152(2), 243. https://doi.org/10.1016/j.ygyno.2018.11.017

Chicago Style (17th ed.) Citation

Varga, Andrea, Sarina Piha-Paul, Patrick A. Ott, Janice M. Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, and Daniela Matei. "Pembrolizumab in Patients with Programmed Death Ligand 1–positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028." Gynecologic Oncology 152, no. 2 (2019): 243. https://doi.org/10.1016/j.ygyno.2018.11.017.

MLA (9th ed.) Citation

Varga, Andrea, et al. "Pembrolizumab in Patients with Programmed Death Ligand 1–positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028." Gynecologic Oncology, vol. 152, no. 2, 2019, p. 243, https://doi.org/10.1016/j.ygyno.2018.11.017.